INM
HEALTHCAREInMed Pharmaceuticals Inc
$0.73-0.01 (-1.84%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving INM Today?
No stock-specific AI insight has been generated for INM yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.58$5.50
$0.73
Fundamentals
Market Cap$2M
P/E Ratio—
EPS$-2.88
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin-1.7%
Debt / Equity—
Trading
Volume17K
Avg Volume (10D)—
Shares Outstanding3.3M
INM News
20 articles- InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- InMed Pharmaceuticals Amends Preferred Investment OptionsYahoo Finance·Apr 27, 2026
- InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price ComplianceYahoo Finance·Mar 27, 2026
- InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease ProgramYahoo Finance·Mar 23, 2026
- Sidoti Events, LLC's March Small-Cap Virtual ConferenceYahoo Finance·Mar 18, 2026
- InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical TrialYahoo Finance·Mar 9, 2026
- InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development PipelineYahoo Finance·Mar 6, 2026
- InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business UpdateYahoo Finance·Feb 11, 2026
- InMed Announces Results of 2025 Annual General and Special MeetingYahoo Finance·Dec 18, 2025
- InMed Provides Update on BayMedica Commercial BusinessYahoo Finance·Dec 12, 2025
- Life Sciences Virtual Investor Forum Agenda Announced for December 11thYahoo Finance·Dec 9, 2025
- InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901Yahoo Finance·Nov 18, 2025
- InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business UpdateYahoo Finance·Nov 6, 2025
- InMed Pharmaceuticals Appoints Mr. John Bathery to Its Board of DirectorsYahoo Finance·Oct 16, 2025
- InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of DirectorsYahoo Finance·Oct 9, 2025
- InMed Pharmaceuticals reports FY25 EPS ($8.36) vs ($20.14) last yearYahoo Finance·Sep 24, 2025
- InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business UpdateYahoo Finance·Sep 23, 2025
- Life Sciences Virtual Investor Forum: Presentations Now Available for Online ViewingYahoo Finance·Sep 18, 2025
- InMed to Present at the Life Sciences Virtual Investor Forum September 18th, 2025Yahoo Finance·Sep 16, 2025
- Life Science Virtual Investor Forum Agenda Announced for September 18thYahoo Finance·Sep 16, 2025
All 20 articles loaded
Price Data
Open$0.74
Previous Close$0.74
Day High$0.76
Day Low$0.73
52 Week High$5.50
52 Week Low$0.58
52-Week Range
$0.58$5.50
$0.73
Fundamentals
Market Cap$2M
P/E Ratio—
EPS$-2.88
Dividend Yield—
Dividend / Share—
ROE-1.0%
Profit Margin-1.7%
Debt / Equity—
Trading
Volume17K
Avg Volume (10D)—
Shares Outstanding3.3M
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical-stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company is headquartered in Vancouver, Canada.
HEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDRUG MANUFACTURERS - SPECIALTY & GENERIC
CIK—
Composite FIGI—
Share Class FIGI—